A Study on Whether Patients Prefer the Spiriva ® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)

Condition:   Pulmonary Disease, Chronic Obstructive Interventions:   Drug: Tiotropium Respimat® (T1);   Drug: Tiotropium Handihaler® (T2) Sponsor:   Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials